Novel Approaches in Discovery and Design of Antibody-Based Therapeutics
A special issue of Antibodies (ISSN 2073-4468).
Deadline for manuscript submissions: closed (20 January 2023) | Viewed by 501
Special Issue Editor
Interests: therapeutic antibodies; antibody technology; antibody fragments; molecular dynamics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Since the approval of muromonab-CD3 in 1986, antibodies have gone from being widely considered as nothing more than academic curiosities, with insurmountable discovery, development, manufacturing, processing, regulatory, supply chain, delivery and immunogenicity issues, to becoming mainstream and frontline therapeutic options for clinicians. The story is one of human endeavour and technological advance in overcoming a challenge, where the potential benefits to patients from antibodies’ positive attributes have been enough to maintain belief in the minds of pioneering scientists.
Since 1976, when the invention of hybridoma solved the issues of product definition and consistency of supply, the technology has advanced rapidly, spanning the fields of molecular biology, structural biology, computer-aided drug design, process biology and, more recently, artificial intelligence, to address ever more unmet patient need.
In this Special Issue, we aim to highlight technological approaches currently being developed and applied to the invention of antibody-based products and look forward to the approval of ever more efficacious and safe medicines that build on the legacy of Orthoclone OKT3.
Dr. Alastair Lawson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibodies is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- variable region discovery
- antibody engineering
- rational design
- structure-based design
- single chain designs
- format engineering
- antibody conjugates
- new technologies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
